| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Revenue | 149,002 | 172,908 | 151,654 | 153,104 |
| Cost of products and services revenue | 48,695 | 47,824 | 45,261 | 48,884 |
| Gross profit | 100,307 | 125,084 | 106,393 | 104,220 |
| Research and development | 57,194 | 61,224 | 66,174 | 62,918 |
| Selling, general and administrative | 75,355 | 74,434 | 81,704 | 83,039 |
| Gain on settlement | 0 | 40,700 | - | - |
| Total operating expenses | 132,549 | 94,958 | 147,878 | 145,957 |
| Loss from operations | -32,242 | 30,126 | -41,485 | -41,737 |
| Interest income | 5,199 | 4,271 | 4,971 | 4,715 |
| Interest expense | -3 | 3 | 2 | 1 |
| Other income (expense), net | -1,165 | 2,603 | 2,078 | -56 |
| Total other income | 4,037 | 6,871 | 7,047 | 4,658 |
| Loss before provision for income taxes | -28,205 | 36,997 | -34,438 | -37,079 |
| (benefit from) provision for income taxes | -733 | 2,459 | 1,315 | 818 |
| Net loss | -27,472 | 34,538 | -35,753 | -37,897 |
| Net loss per share, basic (in dollars per share) | -0.22 | 0.28 | -0.3 | -0.32 |
| Net loss per share, diluted (in dollars per share) | -0.22 | 0.28 | -0.3 | -0.32 |
| Weighted-average shares used to compute net loss per share, basic (in shares) | 125,502,291 | 123,755,409 | 120,733,030 | 120,066,972 |
| Weighted-average shares used to compute net loss per share, diluted (in shares) | 125,502,291 | 124,509,720 | 120,733,030 | 120,066,972 |
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)